Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting

What Was Tested

This observational study paper looks at Semaglutide in the context of fat loss, obesity & body recomposition.

Obesity is defined as excess adipose tissue causing a deterioration in health, but diagnosing the causes and deciding on treatment can be challenging.

This study investigated the clinical response to semaglutide as a weight loss treatment in a real-world setting.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

The data were collected from the electronic medical records (EMR) from outpatient clinics between July 2021 to March 2023.

All participants were older than 18 years, with no history of bariatric surgery within 1 year, and had a least one prescription of injectable semaglutide.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The methods mention a period of 6 months.

Weight loss after 6 months was also evaluated.

The primary outcome was weight change at 3 months.

Weight loss in those patients who attended at 6 months was a secondary outcome.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Obesity, Weight Loss and Semaglutide.

Author keywords: GLP-1, Real-world and Weight management.

What This Means in Plain Language

The paper is a randomized study of Semaglutide in people with fat loss, obesity & body recomposition over 6 months.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Endocrine), a journal based in United States.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.